Skip to content

Epidaurus · Treatment Guide · Therapeutic Interventions

Going abroad for —

Clinical Trial Access

Access to clinical trials and experimental treatments

The country comparison

Which countries are best for clinical trial access

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 Hungary HU 4.5/5 Good Hungary demonstrates exceptional clinical trial infrastructure and regulatory efficiency, with 1,049 active trials (far exceeding 200), a 60-day approval process (sometimes 10-15 days via VHP+), and multiple world-cla... Full report
    The evidence behind this score 6 cited points
    • 1,044-1,049 active clinical trials with 93% international sponsorship and 599 open/recruiting on ClinicalTrials.gov as of Feb 2024 (Cromos Pharma 2024)
    • Regulatory approval in 60 days via EU CTIS; VHP+ reduces to 10-15 days for qualifying multinational trials (Pharma Boardroom 2023)
    • Four world-class research centers: Semmelweis University (3 accredited Phase I units, 200 trials/year, 3,000+ active patients) and National Institute of Oncology Budapest (first OECI-accredited Comprehensive Cancer Center in CEE, 100+ oncology trials/year) plus 4 regional oncology centers (Semmelweis/NIO/Cromos 2024)
    • Compassionate use legislation established (Act XCV 2005, Section 25/C effective 2016); manufacturers required to provide investigational drugs at no cost; mandatory trial sponsor reimbursement of international patient travel and accommodation (PMC 2016, Cromos 2024)
    • ~20,000 patients annually access innovative therapies through clinical trial participation; EU clinical trial registries (CTIS, ClinicalTrials.gov) provide clear information accessibility (Cromos 2024, US Commercial Service 2024)
    • No dedicated medical tourism infrastructure for trial enrollment and no formal international patient outreach programs, distinguishing Hungary from Score 5 destinations (Report Medical Tourism Implications)

    Read the full Hungary report →

  2. 2 Singapore SG 4.5/5 Good Singapore demonstrates solid clinical trial access with efficient regulatory processes, a substantial trial portfolio averaging ~220 trials annually, and world-class oncology research infrastructure led by NCCS. The 3... Full report
    The evidence behind this score 4 cited points
    • Regulatory efficiency: ~30 working days for CTA approval; IRB Mutual Recognition Agreement effective April 2025; UK-Singapore Regulatory Innovation Corridor launched December 2025 for joint regulatory pathways in oncology and breakthrough therapies
    • Trial volume and infrastructure: Approximately 1,179 trials hosted 2020-2025 (averaging ~220/year); NCCS manages 220+ ongoing Phase I-IV clinical trials; multiple JCI-accredited hospitals (21 total) provide baseline quality standards
    • Access mechanisms: ClinicalTrials.SG portal launched July 2024 providing searchable trial listings; English-language regulatory environment; HSA Special Access Route (compassionate use) offers 14-working-day approval for named-patient access to unregistered investigational products
    • Notable limitations: No dedicated international patient program or formal visa category for trial participants; ancillary care costs billed at foreigner/private rates; 2024 trial volume declined to 179 from peak of 276 in 2021; compassionate use framework lacks public drug inventory

    Read the full Singapore report →

  3. 3 Spain ES 4.5/5 Good Spain demonstrates exceptional infrastructure for clinical trial access with 962 authorized trials (EU record), multiple world-class research centers, and streamlined regulatory processes (26-day fast-track for Phase ... Full report
    The evidence behind this score 5 cited points
    • 962 trials authorized in 2025 — highest in EU — with 758 multinational studies and AEMPS 26-day fast-track for Phase I oncology/rare disease trials
    • Multiple world-renowned clinical research centers including VHIO (1,555+ active trials in 2025), Hospital Clínic, CNIO, and SJD Barcelona (second-largest pediatric trial unit in Europe)
    • Comprehensive compassionate use framework under Royal Decree 1015/2009 with 100% authorization within 2 business days, free-of-charge provision, and post-trial supply mandate requiring sponsors to continue providing investigational drugs until market authorization
    • Dedicated international patient infrastructure: SJD Barcelona operates a one-stop-shop for cross-border pediatric patients; Barcelona International Hospitals network markets 3,000+ active trials to international patients with multilingual staff and personal coordinators
    • Strong regulatory efficiency and international integration: Spain leads FAST-EU multinational fast-track initiative launching January 2026; Catalonia ranks 2nd globally per capita for trial participations (behind only Denmark); VHIO contributed to 8 of 26 EMA-recommended substances in 2025

    Read the full Spain report →

  4. 4 Colombia CO 4.5/5 Good Colombia demonstrates a strong regulatory framework with landmark 2024 legislation enabling 7-30 day approvals, substantially exceeding Score 4 benchmarks. It maintains 240 actively recruiting trials and 150+ certifie... Full report
    The evidence behind this score 6 cited points
    • Landmark 2024 'Confianza Supervisada' legislation enables 7-day tacit approval for common-risk trials and 30-day review for high-risk trials, setting legally enforceable timelines among Latin America's fastest
    • 240 actively recruiting/imminently recruiting trials on ClinicalTrials.gov (0.39% of global registered trials); 4th in Latin America by density
    • 150+ INVIMA/GCP-certified research centers with multiple JCI-accredited hospitals including Fundación Valle del Lili, Santa Fe de Bogotá, and Hospital Pablo Tobón Uribe
    • Formal expanded access programs with 10-day INVIMA evaluation timelines and mandated post-trial access continuation at sponsor expense
    • World-unique PSEN1 E280A Alzheimer's kindred (~6,000 family members) hosting landmark Genentech/Roche/NIH-funded prevention trial unavailable anywhere else globally
    • Explicit gaps: No dedicated clinical-trial medical tourism pathway exists (clinical trials not yet primary marketed medical tourism offering); very limited Phase I trials; language barriers remain at most sites

    Read the full Colombia report →

  5. 5 Israel IL 4.5/5 Good Israel demonstrates exceptional clinical trial access with 8,290+ registered studies and world-leading immuno-oncology programs at five major research centers actively enrolling international patients. The regulatory ... Full report
    The evidence behind this score 5 cited points
    • 8,290+ clinical studies with Israeli participation on ClinicalTrials.gov, 1,420 planned/ongoing studies, 650+ oncology trials—far exceeds 200+ trial threshold
    • Five major academic medical centers (Sheba, Hadassah, Rambam, TAMC, Ichilov) with Sheba ranked World's Best Hospital 6 consecutive years; unique TIL therapy for ovarian cancer unavailable elsewhere globally
    • 3,284 compassionate use treatments administered 2020-2024 with 60% subsequently approved to national health basket, plus guaranteed 3-year post-trial free drug access under Ministry of Health Guideline 14
    • Streamlined regulatory pathway with standard 2-4 month approval and March 2025 fast-track reducing drug approval to 70 days for FDA/EMA-approved medications; FDA Project Orbis membership for concurrent oncology review
    • Dedicated medical tourism infrastructure with Ministry-licensed ResultMed, structured international patient departments at all major centers providing multilingual coordination (Hebrew, English, Russian, Arabic)

    Read the full Israel report →

  6. 6 Germany DE 4.0/5 Good Germany demonstrates excellent trial volume (2,774 active trials, 3rd in Europe), world-class research infrastructure (Charité, DKFZ, six NCT sites, eight DKTK hospitals), and streamlined regulatory approval (26–31 da... Full report
    The evidence behind this score 5 cited points
    • 2,774 active clinical trials as of March 2025, ranking 3rd in Europe; 332 of 392 new 2025 applications to PEI are multinational trials
    • Medical Research Act reduced mononational trial authorization to 26–31 days (well below Score 5 threshold of <60 days); Specialized Ethics Committee operational since 1 July 2025
    • Multiple world-class research centers: Charité coordinates 600+ trials annually; Heidelberg University Hospital operates dedicated Medical International Office; DKFZ is Europe's largest biomedical research institute; six NCT sites and eight DKTK partner hospitals
    • AMHV compassionate use framework with BfArM/PEI oversight; EU's first psilocybin compassionate use program approved July 2025
    • Explicit gaps: 'Germany lacks a dedicated clinical trial medical tourism infrastructure' and 'no national program mandating multilingual trial information'; trial consent forms and communications frequently available in German only

    Read the full Germany report →

  7. 7 South Korea KR 4.0/5 Good South Korea operates 747+ active clinical trials annually with fast regulatory approval (4–8 weeks combined MFDS and IRB review), well above the 100+ threshold for Score 4. The country hosts 5+ world-renowned clinical... Full report
    The evidence behind this score 5 cited points
    • 747 MFDS-approved clinical trials in 2024 (half multinational), with 636 IND approvals in 2025 and 70% from international sponsors; combined MFDS + IRB approval in 4–8 weeks (far exceeding 60–120 day benchmark)
    • Five major academic medical centers—SNUH, Asan Medical Center, Samsung Medical Center, Severance Hospital, and Seoul National University Bundang Hospital—collectively completed 2,258 studies over five years; Asan conducts 300+ trials annually with 20% Phase I; SNUH's 24/7 Phase I oncology ward managed 525 trials over 2013–2018
    • 26+ dedicated Phase I units with 714+ research beds; 200+ MFDS-certified clinical trial sites and 15,000+ research professionals; 99.6% national health insurance enrollment enabling rich longitudinal EMRs for patient identification
    • Compassionate use program available under Pharmaceutical Affairs Act Articles 28–29 and Article 34(4), with individual patient approvals in 7 days and multiple-patient approvals in 30 days for life-threatening conditions; KODC-Anova partnership expanding framework reach
    • Critical gap: no dedicated national program linking medical tourists with clinical trial enrollment; CRIS registry operates entirely in Korean; international enrollment requires physician-to-physician referral rather than public self-service pathway; no publicly documented international patient outcomes in clinical trials

    Read the full South Korea report →

  8. 8 United States US 4.0/5 Good The United States demonstrates exceptional clinical trial infrastructure with 500,000+ registered studies and a 99% expanded access approval rate, operating world-class research centers like MD Anderson, Mayo Clinic, ... Full report
    The evidence behind this score 4 cited points
    • 197,090 total registered trials (1999-June 2025) with 500,000+ studies in ClinicalTrials.gov, world's largest clinical trial registry
    • 99% authorization rate for ~9,000 expanded access applications over five years, demonstrating exceptional compassionate use infrastructure
    • Multiple world-renowned clinical research centers with international patient programs: MD Anderson (International Center with language support), Mayo Clinic (1.3M patients annually from 130 countries), Johns Hopkins, Cleveland Clinic, NIH Clinical Center (500,000+ international participants since 1953)
    • Priority given to US citizens and residents limits international recruitment, and international patients must self-fund travel and obtain B-2 visas, creating significant access barriers

    Read the full United States report →

  9. 9 United Arab Emirates AE 3.5/5 Moderate The UAE demonstrates a moderately-to-good clinical trial environment with 100+ active trials and world-class research centers (Cleveland Clinic, SSMC, ADHRC) with AAHRPP accreditation. Abu Dhabi's 28-day regulatory ap... Full report
    The evidence behind this score 5 cited points
    • CenterWatch lists 339 active trials in Abu Dhabi and 295 in Dubai; ADHRC manages 200+ active studies across 22 therapeutic areas
    • Abu Dhabi Department of Health achieves 28-day clinical trial approvals; federal MOHAP process takes 6-12 months, creating inconsistent regulatory timelines
    • Three major AAHRPP-accredited research centers: Cleveland Clinic Abu Dhabi (March 2025), Sheikh Shakhbout Medical City with Mayo Clinic partnership, and PureHealth's SEHA/ADHRC (April 2026)
    • Federal Decree-Law 38/2024 establishes compassionate use and Emergency Use Authorization pathways, but implementing regulations remain unpublished as of early 2026
    • Report states no dedicated international patient clinical trial program exists; most UAE-based trials recruit patients residing in UAE rather than through deliberate international outreach

    Read the full United Arab Emirates report →

  10. 10 Brazil BR 3.5/5 Moderate Brazil operates 1,500+ active clinical trials and underwent regulatory transformation via Law 14.874/2024, reducing approval timelines to 30–90 business days and meeting efficiency thresholds. Multiple world-class res... Full report
    The evidence behind this score 5 cited points
    • Brazil maintains 1,500+ active clinical trials with 4,735 recruiting in REBEC (national registry) as of October 2025, exceeding the 100+ threshold for Score 4
    • Law 14.874/2024 (effective August 2024) reduced ethics committee review from 180 days to 30 business days and ANVISA regulatory review from 12+ months to 90 business days, with parallel simultaneous review now permitted
    • No formal framework or dedicated pathway facilitates foreign patient enrollment; the report states international patients must navigate trials independently, establish direct contact with Portuguese-only administrative staff, and face officially-mandated Portuguese-language documentation requirements
    • Expanded access programs exist under RDC 38/2013, but neither existing nor proposed revisions explicitly address eligibility for foreign or non-resident patients; access in practice is processed through Brazilian physicians at Brazilian facilities
    • Hospital Israelita Albert Einstein operates an International Patient Center with multilingual coordinators, but public academic research centers (HCFMUSP, INCA) are predominantly Portuguese-only; geographic concentration (77% of centers in South/Southeast) limits access for international patients

    Read the full Brazil report →

  11. 11 United Kingdom GB 3.5/5 Moderate The UK combines world-leading clinical research infrastructure and a newly reformed regulatory environment (April 2026) with excellent Phase I oncology units, but lacks any dedicated pathway or infrastructure for inte... Full report
    The evidence behind this score 5 cited points
    • 578 pharmaceutical interventional commercial trials initiated in 2024 with 41-day average combined regulatory approval, representing the most significant UK clinical trial regulatory overhaul in over two decades
    • The Christie Hospital operates world's largest Phase I clinical trials unit (~200 simultaneous trials, ~2,400 patients/year); Royal Marsden/ICR enrolls ~300 patients annually in Phase I studies
    • EAMS compassionate use program has benefited 1,200+ patients since 2014 but explicitly excludes non-UK residents; no structured expanded access pathway exists for international patients
    • Industry trial participants declined 25% from 2022/23 to 2024/25 (lowest in eight years), with only 27% of commercial studies opening to recruitment within 60 days, despite strong infrastructure
    • Report explicitly states 'No dedicated medical tourism clinical trial infrastructure exists' and access for international patients is 'sometimes possible, but can be very difficult' and relies on opaque, inconsistent physician referrals

    Read the full United Kingdom report →

  12. 12 Japan JP 3.5/5 Moderate Japan operates world-class clinical research infrastructure with 9,000+ trials and multiple internationally-recognized centers (NCCH, Keio, Osaka, Juntendo), supported by an established regulatory framework and struct... Full report
    The evidence behind this score 3 cited points
    • 9,000+ trials registered on ClinicalTrials.gov and 15,000+ on jRCT, with NCCH conducting 507 registration-directed trials and maintaining seven authorized medical coordinating agents for international patients
    • Only 31 expanded access clinical trials conducted over five years (1.5% activation rate); no single-patient emergency access pathway, restricting access to experimental drugs until late in development phases
    • Language barriers identified as 'the most significant practical obstacle,' with over 50% of non-native Japanese speakers requiring professional medical interpretation; clinical protocols, consent documents, and safety monitoring conducted entirely in Japanese

    Read the full Japan report →

  13. 13 Mexico MX 3.5/5 Moderate Mexico operates a substantial clinical trials market with ~5,000 registered trials and multiple world-class research institutions (INCan, INCMNSZ, CHRISTUS Muguerza), placing it above the moderate tier baseline. Howev... Full report
    The evidence behind this score 5 cited points
    • ~5,000 clinical studies registered on ClinicalTrials.gov with 2,354 in Phase III as of April 2024; Mexico is Latin America's second-largest clinical trials market at USD 379.51 million (2025)
    • INCan holds ESMO designation and treats 5,000+ new cancer patients annually; CHRISTUS Muguerza maintains CAP-certified laboratory and unbroken JCI accreditation since 2007
    • Historical approval timelines of 6–10 months total (3–6 months institutional review + 90-day COFEPRIS evaluation), among the slowest in Latin America, though COFEPRIS announced 45-day target
    • No formal national expanded access or compassionate use program; access to investigational treatments is case-by-case through COFEPRIS or multinational manufacturer programs
    • All clinical trial documentation must be in Spanish; no multilingual trial coordination infrastructure at national level despite 1.4–3 million annual medical tourists

    Read the full Mexico report →

  14. 14 Malaysia MY 3.5/5 Moderate Malaysia exceeds Score 3 with 267 active clinical trials, ICH-GCP aligned regulatory framework (~120 days startup), and multiple JCI-accredited research centers conducting international trials. However, it falls short... Full report
    The evidence behind this score 4 cited points
    • 267 sponsored clinical trials in 2024, ranked #2 in Southeast Asia and #28 globally; parallel NPRA/MREC submission enables ~120-day regulatory startup within Score 4 range
    • Three Phase I accredited research units (SGH fully accredited, Hospital Ampang accredited 2024, UMMC pending 2026); Institut Kanser Negara and 50+ total trial sites across 20+ therapeutic areas
    • No dedicated international patient enrollment pathway or coordinator network; clinical trial and medical tourism sectors remain siloed despite strong MHTC medical visa and hospital support infrastructure
    • Compassionate use available under CDCR 1984 Reg. 15(6) but primarily designed as post-trial extension; international patients without prior Malaysian trial enrollment require Malaysian physician involvement; no named patient programs

    Read the full Malaysia report →

  15. 15 Poland PL 3.5/5 Moderate Poland offers international medical tourists substantial access to clinical trials through an extensive, internationally-recruited trial portfolio (1,395 open studies, 73% international sponsorship) and efficient regu... Full report
    The evidence behind this score 5 cited points
    • 1,395 open studies registered with 73% international sponsorship, placing Poland among Europe's top clinical research hubs
    • Regulatory approval timeline of 60 days meets efficiency benchmarks, and the 2023 Clinical Trials Act modernized the framework with EU alignment
    • Maria Skłodowska-Curie NRI manages 650+ trials with EORTC membership, JCI Clinical Trials Center provides modern facilities, and PCTN operates 23 Clinical Trial Support Centres
    • Complete absence of formal compassionate use or expanded access programs, explicitly identified as the most consequential deficiency for international patients seeking experimental treatments outside formal trials
    • Mandatory Polish-language informed consent documentation and no national translation services for international patients, combined with no dedicated medical tourism integration or facilitation agencies

    Read the full Poland report →

  16. 16 Thailand TH 3.5/5 Moderate Thailand demonstrates substantial clinical trial infrastructure with 527 trials in 2024 and 1,200+ registered on ClinicalTrials.gov, exceeding the 50+ threshold for Score 3. It has 2-3 recognized clinical research cen... Full report
    The evidence behind this score 5 cited points
    • 527 clinical trials conducted in 2024 with over 11,000 conducted since 1999 (highest in Southeast Asia)
    • Thai FDA Ethics Committee approvals take several months, with no streamlined process for international patients
    • No documented compassionate use or expanded access programs for international patients in Thailand
    • Thailand has more JCI-accredited hospitals than any other Asian country, with Siriraj and Bumrungrad offering clinical trial access
    • Thai Clinical Trials Registry established 2009, WHO primary registry since August 2013 with all registrations in English

    Read the full Thailand report →

  17. 17 India IN 3.0/5 Moderate India has exceptional clinical trial volume (94,730+ trials since 2000) and world-class research infrastructure (Tata Memorial, AIIMS, 80+ trial-conducting hospitals), with efficient regulatory approval (90 days) that... Full report
    The evidence behind this score 6 cited points
    • India has 94,730 trials registered since 2000, third-largest destination globally with 18,000 new trials in 2024 alone (CDSCO regulatory data)
    • Regulatory approval timeline of 90 working days accommodates international participation within reasonable efficiency range; reforms increased approvals 67% between 2019-2023 (CDSCO data)
    • Multiple world-class research centers exist including Tata Memorial Center (10+ cancer institutes registering 120,000 cancer patients annually), AIIMS, and ICMR-Network for Phase 1 Clinical Trials (established May 2024)
    • Compassionate use framework is nascent stage lacking formal policies and laws; June 2020 proposed amendment for expanded access imports remains in draft and has not been incorporated (Ministry of Health proposal, 5-year gap)
    • No documented explicit pathways for international patients: 'international patient-specific policies and infrastructure for facilitating medical tourism for clinical trial participation remain underdeveloped'; no dedicated facilitators, visa programs, or international patient coordinators identified
    • Medical tourism infrastructure (650,000 foreign tourists in 2024, $18.2 billion market) is disconnected from clinical trial access with no documented integration or support services for international trial participants

    Read the full India report →

  18. 18 Turkey TR 3.0/5 Moderate Turkey demonstrates moderate clinical trial access with 2,699 active trials and EU-aligned regulatory processes achieving 4-6 week approvals. However, the absence of international IRB accreditation across all 78 insti... Full report
    The evidence behind this score 6 cited points
    • 2,699 active clinical trials as of 2023 with 750 industry-sponsored interventional studies
    • No international IRB accreditation exists among 78 Institutional Review Boards across 34 provinces
    • 4-6 week approval timeline for clinical trials through EU-aligned TİTCK regulatory processes
    • 42 compassionate use programs since 2006 treating 1,247 patients, focused on oncology conditions
    • 84% of trials locally sponsored, indicating limited participation in multinational international trials
    • Absence of dedicated international patient coordinators or specialized medical tourism packages for clinical trial participation

    Read the full Turkey report →

  19. 19 Jordan JO 3.0/5 Moderate Jordan operates with established regulatory processes (JFDA, 30-90 day approvals) and registered 484 clinical trials, with KHCC achieving AAHRPP accreditation and serving as the EORTC Middle East Co-ordinating Office.... Full report
    The evidence behind this score 5 cited points
    • 484 registered clinical trials per 2025 systematic review (362 interventional), exceeding Score 3 volume threshold but recruitment explicitly documented as 'very limited' domestically
    • KHCC holds AAHRPP accreditation (8th globally) and serves as EORTC Middle East Co-ordinating Office with 6 active EORTC trial partnerships, but international recruitment not systematically marketed
    • No formal JFDA-level expanded access or compassionate use program for international patients; only 2 expanded access records in Jordan's ClinicalTrials.gov history
    • Regulatory approval timeline 30–90 days is competitive within MENA, but regulations lack specific international patient enrollment provisions
    • 13 CROs in Amman (IPRC 180 beds, JCPR 120 beds) hold FDA/EMA credentials but primary orientation is Phase I bioequivalence studies for healthy volunteers, not disease-treatment trials

    Read the full Jordan report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for clinical trial access, top to bottom. How we score →

  1. 5/5 Excellent

    - 200+ active clinical trials with clear international recruitment - Streamlined regulatory processes specifically accommodating international patients (approval times <60 days) - 5+ world-renowned clinical research centers actively enrolling medical tourists - Comprehensive expanded access/compassionate use programs available to international patients - Dedicated medical tourism infrastructure supporting clinical trial participation - Government policies actively promoting international clinical trial participation - Multi-language trial information and patient support services - Evidence of successful outcomes for international trial participants across multiple therapeutic areas

  2. 4/5 Good

    - 100+ active clinical trials with some international recruitment capability - Established regulatory framework allowing international participation with reasonable efficiency (60-120 day approvals) - 3+ recognized clinical research centers accepting international patients - Some expanded access programs available to international patients - Basic support services for international trial participants - Clear information resources about clinical trial opportunities - Evidence of successful international patient outcomes in clinical trials

  3. 3/5 Moderate

    - 50+ active clinical trials with limited international recruitment - Standard regulatory processes that accommodate international patients without special provisions - 1-2 clinical research centers with international outreach - Limited expanded access programs or case-by-case consideration - Basic infrastructure for supporting international patients in trials - Some information available about clinical trial opportunities - Mixed evidence of international patient experiences

  4. 2/5 Poor

    - <50 active clinical trials with minimal international recruitment - Regulatory barriers or inefficiencies that discourage international participation - Limited clinical research infrastructure - No formal expanded access programs for international patients - Minimal support services for international trial participants - Poor information accessibility about trial opportunities - Limited evidence of successful international patient outcomes

  5. 1/5 Very Poor / Unavailable

    - Minimal clinical trial activity (<25 active trials) - Regulatory prohibition or significant barriers to international patient participation - No specialized clinical research centers accepting international patients - No expanded access programs available - No support infrastructure for international patients - No accessible information about clinical trial opportunities - No evidence of international patients successfully accessing experimental treatments

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source clinirx.com/conducting-clinical-trials-in-india Cited in Clinical Trial Access in India
  2. Untitled source www.ctri.nic.in Cited in Clinical Trial Access in India
  3. Untitled source ankarasehir.saglik.gov.tr/EN-835513/clinical-research-center.html Cited in Clinical Trial Access in Turkey
  4. Untitled source arriveturkey.com/health-tourism/medical-tourism-in-turkey-comprehensive-guide Cited in Clinical Trial Access in Turkey
  5. Untitled source badaniakliniczne.pl Cited in Clinical Trial Access in Poland
  6. Untitled source bagchilaw.com/2019/11/12/a-guide-to-india-clinical-trials-regulations-part-1-history-overview Cited in Clinical Trial Access in India
  7. Untitled source bri.snubh.org/eng_ctc/conts/101001000000000.do Cited in Clinical Trial Access in South Korea
  8. Untitled source cdsco.gov.in/opencms/opencms/en/Clinical-Trial/Global-Clinical-Trial Cited in Clinical Trial Access in India
  9. Untitled source cdsco.gov.in/opencms/opencms/en/Drugs/New-Drugs Cited in Clinical Trial Access in India
  10. Untitled source cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadAlertsFiles/Guidance_for_New_Drug_Approval-23july2.pdf Cited in Clinical Trial Access in India
  11. Untitled source chemxpert.com/blog/drug-approval-process-in-india Cited in Clinical Trial Access in India
  12. Untitled source clinpharm.pro/clinical-trials-in-rare-diseases Cited in Clinical Trial Access in Poland
  13. Untitled source clinregs.niaid.nih.gov/country/india Cited in Clinical Trial Access in India
  14. Untitled source cms-lawnow.com/en/ealerts/2023/07/hungary-s-pharma-authority-to-merge-with-the-national-public-health-centre Cited in Clinical Trial Access in Hungary
  15. Untitled source corporate.cyrilamarchandblogs.com/2023/02/use-of-unapproved-drugs-in-india-on-compassionate-grounds-unravelling-the-regulatory-conundrum Cited in Clinical Trial Access in India
  16. Untitled source credevo.com/articles/2024/02/15/top-8-reasons-to-choose-india-as-your-clinical-trial-destination-advantages-and-strategic-benefits Cited in Clinical Trial Access in India
  17. Untitled source credevo.com/articles/2025/07/15/dcgi-approval-in-india-a-complete-guide-to-drug-regulations-clinical-trials-patient-safety Cited in Clinical Trial Access in India
  18. Untitled source cromospharma.com/exploring-turkiye-s-edge-in-clinical-research-insights-into-hospital-systems-and-regulatory-framework Cited in Clinical Trial Access in Turkey
  19. Untitled source cromospharma.com/turkiye-a-hidden-gem-in-clinical-research Cited in Clinical Trial Access in Turkey
  20. Untitled source distefar.com/en/spain-attracts-hundreds-of-clinical-trials-offering-a-last-hope-to-thousands-of-patients-without-research-we-are-lost Cited in Clinical Trial Access in Spain
  21. Untitled source dmcquote.com/guides/medical-tourism-thailand Cited in Clinical Trial Access in Thailand
  22. Untitled source ebmresearch.com Cited in Clinical Trial Access in Turkey
  23. Untitled source en.wikipedia.org/wiki/Clinical_Trials_Registry_%E2%80%93_India Cited in Clinical Trial Access in India
  24. Untitled source en.wikipedia.org/wiki/Expanded_access Cited in Clinical Trial Access in United States, Clinical Trial Access in Turkey

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Therapeutic Interventions

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Clinical Trial Access

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison